Journal article
Risk of arterial and venous thrombotic events among patients with COVID-19: a multi-national collaboration of regulatory agencies from Canada, Europe, and United States
- Abstract:
-
Purpose: Few studies have examined how the absolute risk of thromboembolism with COVID-19 has evolved over time across different countries. Researchers from the European Medicines Agency, Health Canada, and the United States (US) Food and Drug Administration established a collaboration to evaluate the absolute risk of arterial (ATE) and venous thromboembolism (VTE) in the 90 days after diagnosis of COVID-19 in the ambulatory (eg, outpatient, emergency department, nursing facility) setting from seven countries across North America (Canada, US) and Europe (England, Germany, Italy, Netherlands, and Spain) within periods before and during COVID-19 vaccine availability.
Patients and Methods: We conducted cohort studies of patients initially diagnosed with COVID-19 in the ambulatory setting from the seven specified countries. Patients were followed for 90 days after COVID-19 diagnosis. The primary outcomes were ATE and VTE over 90 days from diagnosis date. We measured country-level estimates of 90-day absolute risk (with 95% confidence intervals) of ATE and VTE.
Results: The seven cohorts included 1,061,565 patients initially diagnosed with COVID-19 in the ambulatory setting before COVID-19 vaccines were available (through November 2020). The 90-day absolute risk of ATE during this period ranged from 0.11% (0.09– 0.13%) in Canada to 1.01% (0.97– 1.05%) in the US, and the 90-day absolute risk of VTE ranged from 0.23% (0.21– 0.26%) in Canada to 0.84% (0.80– 0.89%) in England. The seven cohorts included 3,544,062 patients with COVID-19 during vaccine availability (beginning December 2020). The 90-day absolute risk of ATE during this period ranged from 0.06% (0.06– 0.07%) in England to 1.04% (1.01– 1.06%) in the US, and the 90-day absolute risk of VTE ranged from 0.25% (0.24– 0.26%) in England to 1.02% (0.99– 1.04%) in the US.
Conclusion: There was heterogeneity by country in 90-day absolute risk of ATE and VTE after ambulatory COVID-19 diagnosis both before and during COVID-19 vaccine availability.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.7MB, Terms of use)
-
- Publisher copy:
- 10.2147/clep.s448980
Authors
+ Canadian Institutes of Health Research
More from this funder
- Funder identifier:
- https://ror.org/01gavpb45
- Publisher:
- Taylor & Francis
- Journal:
- Clinical Epidemiology More from this journal
- Volume:
- 16
- Pages:
- 71-89
- Place of publication:
- New Zealand
- Publication date:
- 2024-02-10
- Acceptance date:
- 2024-01-23
- DOI:
- EISSN:
-
1179-1349
- Pmid:
-
38357585
- Language:
-
English
- Keywords:
- Pubs id:
-
1624851
- Local pid:
-
pubs:1624851
- Deposit date:
-
2025-07-14
- ARK identifier:
Terms of use
- Copyright holder:
- Lo Re III et al
- Copyright date:
- 2024
- Rights statement:
- © 2024 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms and incorporate the Creative Commons Attribution - Non Commercial (unported, 3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
If you are the owner of this record, you can report an update to it here: Report update to this record